modafinil has been researched along with Glioblastoma in 1 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase II, multi-institutional, placebo-controlled randomized trial assessed feasibility of armodafinil 150 mg/day in participants receiving brain RT, from whom we obtained estimates of variability for fatigue, sleepiness, QOL, cognitive function, and treatment effect." | 9.20 | Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. ( Bryant, D; Case, D; Chan, MD; Grisell, D; Lesser, GJ; Lu, L; Monitto, DC; Naughton, MJ; Page, BR; Rapp, SR; Savona, SR; Shah, S; Shaw, EG, 2015) |
| "A phase II, multi-institutional, placebo-controlled randomized trial assessed feasibility of armodafinil 150 mg/day in participants receiving brain RT, from whom we obtained estimates of variability for fatigue, sleepiness, QOL, cognitive function, and treatment effect." | 5.20 | Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. ( Bryant, D; Case, D; Chan, MD; Grisell, D; Lesser, GJ; Lu, L; Monitto, DC; Naughton, MJ; Page, BR; Rapp, SR; Savona, SR; Shah, S; Shaw, EG, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Page, BR | 1 |
| Shaw, EG | 1 |
| Lu, L | 1 |
| Bryant, D | 1 |
| Grisell, D | 1 |
| Lesser, GJ | 1 |
| Monitto, DC | 1 |
| Naughton, MJ | 1 |
| Rapp, SR | 1 |
| Savona, SR | 1 |
| Shah, S | 1 |
| Case, D | 1 |
| Chan, MD | 1 |
1 trial available for modafinil and Glioblastoma
| Article | Year |
|---|---|
Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue.
Topics: Adult; Aged; Benzhydryl Compounds; Brain Neoplasms; Double-Blind Method; Fatigue; Female; Glioblasto | 2015 |